Sign Up Now!
To sign up for our newsletter or print publications, please enter your contact information below.
First Name *
Last Name *
Email Address (Verify) *
We will request your mailing address on the next page.
We will request your mailing address on the next page.

Rylaze FDA Approved as Part of a Treatment Regimen for Pediatric Leukemia and Lymphoma

JHOP - August 2021 Vol 11, No 4 - FDA Updates
Download PDF

On June 30, 2021, the FDA accelerated the approval of asparaginase erwinia chrysanthemi (recombinant)-rywn (Rylaze; Jazz Pharmaceuticals), an asparagine-specific enzyme, as a component of a multidrug chemotherapy regimen for the treatment of acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma in patients aged ≥1 months with hypersensitivity to Escherichia coli–derived asparaginase.

The FDA granted erwinia chrysanthemi an orphan drug designation for this indication. Erwinia chrysanthemi will address the shortages of Erwinia asparaginase (Erwinaze). Rylaze “has the same molecular makeup as Erwinaze. But it’s manufactured differently, and in a more efficient way, so having the option to substitute Rylaze should reduce the likelihood of treatment shortages for these patients in the future,” said Malcolm A. Smith, MD, PhD, Associate Branch Chief for Pediatric Oncology, NCI’s Cancer Therapy Evaluation Program.

Erwinia chrysanthemi can be used as a substitute to Erwinia asparaginase in people with an immune reaction to pegaspargase. These ongoing shortages have been “incredibly stressful to patients and their parents,” said Sumit Gupta, MD, PhD, University of Toronto, and Pediatric Oncologist, Hospital for Sick Children, Toronto, Canada.

The FDA approved erwinia chrysanthemi based on results of an open-label, multicohort, multicenter clinical trial of 102 patients (median age, 10 years; range, 1-24 years) with ALL or lymphoblastic lymphoma and hypersensitivity to asparaginase caused by E coli infection, as part of a multidrug chemotherapy regimen.

The primary end point was achievement and maintenance of nadir serum asparaginase activity (NSAA) >0.1 U/mL. The results of modeling and simulations showed that for a dosage of 25 mg/m2 administered every 48 hours, the proportion of patients maintaining NSAA ≥0.1 U/mL at 48 hours after a dose of erwinia chrysanthemi was 93.6% (95% confidence interval, 92.6%-94.6%).

The most common (>20%) adverse reactions were abnormal liver test, nausea, musculoskeletal pain, fatigue, infection, headache, pyrexia, drug hypersensitivity, febrile neutropenia, decreased appetite, stomatitis, bleeding, and hyperglycemia.

Related Items
FDA Approved Truseltiq for Metastatic Cholangiocarcinoma with the FGFR2 Biomarker
JHOP - August 2021 Vol 11, No 4 published on August 17, 2021 in FDA Updates
FDA Approves Darzalex Faspro plus Pomalyst and Dexamethasone for Multiple Myeloma
Web Exclusives published on August 10, 2021 in FDA Updates
FDA Approves Avapritinib for Advanced Systemic Mastocytosis
Web Exclusives published on August 10, 2021 in FDA Updates
Pembrolizumab plus Lenvatinib Combination Receives Regular Approval for Advanced Endometrial Carcinoma
Web Exclusives published on August 10, 2021 in FDA Updates
Padcev Receives Regular FDA Approval for Locally Advanced or Metastatic Urothelial Cancer
Web Exclusives published on August 10, 2021 in FDA Updates
FDA Alert: Pepaxto (Melphalan Flufenamide) Associated with Increased Risk of Death in Postmarketing Clinical Trial
Web Exclusives published on August 3, 2021 in FDA Updates
Lumakras First FDA-Approved Therapy for Advanced or Metastatic NSCLC with KRAS G12C Mutation
JHOP - June 2021 Vol 11, No 3 published on June 16, 2021 in FDA Updates
Rybrevant First FDA-Approved Therapy for NSCLC with EGFR Exon 20 Insertion Mutations
JHOP - June 2021 Vol 11, No 3 published on June 16, 2021 in FDA Updates
Zynlonta First FDA-Approved CD19-Directed Therapy for Large B-Cell Lymphoma
JHOP - June 2021 Vol 11, No 3 published on June 16, 2021 in FDA Updates
Jemperli First FDA-Approved Immunotherapy for Advanced Endometrial Cancer with dMMR Biomarker
JHOP - June 2021 Vol 11, No 3 published on June 16, 2021 in FDA Updates
Copyright © Green Hill Healthcare Communications, LLC. All rights reserved.